Overview
This unique book provides a thorough overview of developing molecular cancer diagnostic assays, which are the prerequisites for optimal solutions within personalized cancer medicine. The book takes the reader through definitions of the pharmacodiagnostic concept, historical perspectives of the early steps into molecular cancer diagnostics linked to therapy, the basis of different diagnostic molecular techniques, ongoing research, drug-diagnostic co-development, assay validation, clinical trial methodology, regulatory issues around pharmacodiagnostics and future aspects within personalized cancer medicine.
Full Product Details
Author: Jan Trost Jorgensen ,
Henrik Winther
Publisher: Pan Stanford Publishing Pte Ltd
Imprint: Pan Stanford Publishing Pte Ltd
Dimensions:
Width: 15.20cm
, Height: 2.00cm
, Length: 22.90cm
Weight: 0.703kg
ISBN: 9789814241441
ISBN 10: 981424144
Pages: 362
Publication Date: 30 April 2010
Audience:
College/higher education
,
Professional and scholarly
,
Tertiary & Higher Education
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: In Print
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.
Reviews
The editors have recruited a highly experienced group of both academic medical center and industry-based international authors and produced a concise yet thorough overview of the emerging field of integrated diagnostics and personalized medicine. This book emphasizes slide-based companion pharmacodiagnostics, but also covers in depth post-extraction DNA sequence-based and mRNA profiling-based prognostic and predictive tests for both solid tumors and hematologic malignancies. Chapters on test development, regulatory approval and important consideration of test validation and clinical utility round out this impressive work. Not only will academic departments and cancer centers find this book to be an authoritative reference volume, but also the pharmaceutical and biotechnology industries will be able to gain considerable insight that could play a major role in the shaping of their current and future products. --Prof. Jeffrey S. Ross, Albany Medical College, USA The topics and information covered in the book are the ones highly demanded in the current clinical biomarker sciences. This volume has successfully made a comprehensive coverage from all the experts in biomarker discovery, development, clinical trial and statistical validation, and practical use. This is definitely one of the references that everyone in this area should have. --Prof. Jae K. Lee, University of Virginia
""The editors have recruited a highly experienced group of both academic medical center and industry-based international authors and produced a concise yet thorough overview of the emerging field of integrated diagnostics and personalized medicine. This book emphasizes slide-based companion pharmacodiagnostics, but also covers in depth post-extraction DNA sequence-based and mRNA profiling-based prognostic and predictive tests for both solid tumors and hematologic malignancies. Chapters on test development, regulatory approval and important consideration of test validation and clinical utility round out this impressive work. Not only will academic departments and cancer centers find this book to be an authoritative reference volume, but also the pharmaceutical and biotechnology industries will be able to gain considerable insight that could play a major role in the shaping of their current and future products."" --Prof. Jeffrey S. Ross, Albany Medical College, USA ""The topics and information covered in the book are the ones highly demanded in the current clinical biomarker sciences. This volume has successfully made a comprehensive coverage from all the experts in biomarker discovery, development, clinical trial and statistical validation, and practical use. This is definitely one of the references that everyone in this area should have."" --Prof. Jae K. Lee, University of Virginia
Author Information
Dr Jan Trøst Jørgensen holds an MSc degree in pharmacy and a PhD in clinical pharmacy from the Faculty of Pharmaceutical Sciences, University of Copenhagen. He has worked with drug development in biotech and pharmaceutical companies for more than 25 years, and within the last 10 years his focus has been on drug-diagnostic co-development projects within cancer. Dr Jørgensen is a strong supporter of more individualized pharmacotherapy and has published a number of scientific papers on oncology as well as on stratified and personalized medicine.
